Current Headlines

  1. CureDuchenne Expands Collaboration With Prosensa

    CureDuchenne, a U.S. non-profit, announced its plans to expand its long-standing collaboration with biotech Prosensa by $7 million in hopes of accelerating the timelines on four experimental genetic therapies for use in the treatment of Duchenne Muscular Dystrophy (DMD).

  2. 3SBio Licenses Anti-Leukemic Leukotuximab From DiNona

    China-based biotech 3SBio declared that it has signed into an exclusive license with DiNona for the development, production, and commercialization of Leukotiximab in China and the Middle East.

  3. Daily Aspirin Can Lower Deaths Due to Bowel and Stomach Cancers

    An aspirin a day can keep cancer away, according to a large-scale review of available evidence.

  4. AusBiotech Recommends Policy Changes to Boost Australia's Biotechnology Sector
    Australia's key industry group, AusBiotech, has just made a submission to the Senate, calling for changes in the public policy to leverage the country's biotechnology sector. AusBiotech's submission to the Senate Standing Committee on Economics’ “Australian innovation system” Inquiry has specifically asked for a globally competitive tax policy, support for commercialization, incentives for commercial thinking, clinical trial reform, and other incentives for the biotech industry.
  5. Lab-Grown Human GI Cells Hold Promise For Personalized Treatment
    Researchers from the Washington University School of Medicine in St. Louis have developed a way to grow human cells from tissue taken from patients’ gastrointestinal (GI) tract. The scientists hope the technique will lead to the development of personalized treatments for inflammatory bowel conditions in the future.
  6. Cancer Cells Grow On Soft Beds, Study Finds
    A team of scientists at the University of Illinois reported that tumor-repopulating cells prefer soft beds in which to metastasize rather than hard ones. The researchers hope that the research will help pave the way for new types of drugs that target the renewal pathway of the cancer cells.
  7. Researchers Develop Model To Test New Hepatitis B Treatments

    MIT researchers have developed a new technique for studying the lifecycle of the hepatitis B virus, which could help in testing new treatments for the disease.

  8. Protein ZEB1 Culprit In Breast Tumor Radiation Therapy Resistance
    Researchers at the University of Texas MD Anderson Cancer Center in Houston have reported that a protein called zinc finger E-box binding homeobox 1 (ZEB1) may allow breast cancer cells to persist despite radiation treatment.
  9. NIH Scientists Use Subcellular Imaging to Visualize Structures of Brain Receptors

    Researchers at the National Institutes of Health (NIH) have created high-resolution images of the glutamate receptor, a key protein involved in nerve signaling. The study was published online in the journal Nature on August 3, 2014.

  10. FDA Approves The Medicine Company’s Orbactiv For Skin Infections

    The U.S. Food and Drug Administration (FDA) has granted approval to The Medicine Company’s antibacterial drug Orbactiv for the treatment of skin infections.